Back to top
more

Premier (PINC)

(Delayed Data from NSDQ)

$23.34 USD

23.34
1,825,142

+0.67 (2.96%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $23.34 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 45% (137 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

UpHealth, Inc. (UPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

UpHealth, Inc. (UPH) delivered earnings and revenue surprises of 13.04% and 18.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 0% and 29.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Premier, Inc. (PINC) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Premier, Inc. (PINC) Q3 Earnings Match Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 0% and 8.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Alignment Healthcare (ALHC): Can Its 6.5% Jump Turn into More Strength?

by Zacks Equity Research

Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Premier, Inc. (PINC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 7.46% and 0.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Premier, Inc. (PINC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PINC vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

Should Value Investors Buy AMN Healthcare Services (AMN) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PINC or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

Premier, Inc. (PINC) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of -8.77% and 4.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Premier, Inc. (PINC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Premier, Inc. (PINC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 29% Upside in Premier, Inc. (PINC): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 29.1% upside potential for Premier, Inc. (PINC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PINC vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

Are Investors Undervaluing ModivCare (MODV) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Premier, Inc. (PINC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.67% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 20.59% and 95.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -11.54% and 94.60%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Matches Q3 Earnings Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 0% and 2.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 10.61% and 8.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Premier, Inc. (PINC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.